4.6 Letter

Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 198, Issue 4, Pages 790-793

Publisher

WILEY
DOI: 10.1111/bjh.18306

Keywords

-

Categories

Funding

  1. Janssen-Cilag Pty Ltd Australia

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available